Gelsey FT, Schapiro D, Kosa K, Vass CM, Perez-Nieves M, Pierce A, Poon JL, DiBenedetti D, Mansfield C. Perspectives and preferences of people with type 2 diabetes for the attributes of weekly insulin. Diabetes Ther. 2024 Nov;15(11):2367-79. doi: 10.1007/s13300-024-01652-0
Shinde S, Thieu VT, Kwan AYM, Houghton K, Meyers J, Schapiro D. Impact of weight change on glycemic control and metabolic parameters in T2D: a retrospective us study based on real-world data. Diabetes Ther. 2024 Feb;15(2):409-26. doi: 10.1007/s13300-023-01511-4.
Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Bowater RJ, Hartley LC, Lilford RJ. Are cardiovascular trial results systematically different between North America and Europe? A study based on intra-meta-analysis comparisons. Arch Cardiovasc Dis. 2015 Jan;108(1):23-38. doi: 10.1016/j.acvd.2014.03.005
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Godwin SL, Coppings R, Kosa KM, Cates SC. Consumer response to food contamination and recalls: findings from a national survey. J Food Distrib Res. 2012 Mar;43(1):19-26. doi: 10.22004/ag.econ.139445